EFFICACY OF CHRONIC HEART FAILURE COMBINED THERAPY DURING PERLINDOL USAGE IN ELDERLY POST INFARCTION PATIENTS WITH PSYCHOSOMATIC DISORDERS

Aim. To study the efficacy and safety of reversible MAO inhibitor pirlindol (Pyrazidol) in elderly post infarction patients with chronic heart failure (CHF) and affective disorders.Material and methods. 60 patients with CHF of II-III NYHA class 3-4 weeks after myocardial infarction with and anxious...

Full description

Saved in:
Bibliographic Details
Main Authors: M. E. Statsenko, I. A. Tyschenko
Format: Article
Language:English
Published: Столичная издательская компания 2016-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/1137
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227764683505664
author M. E. Statsenko
I. A. Tyschenko
author_facet M. E. Statsenko
I. A. Tyschenko
author_sort M. E. Statsenko
collection DOAJ
description Aim. To study the efficacy and safety of reversible MAO inhibitor pirlindol (Pyrazidol) in elderly post infarction patients with chronic heart failure (CHF) and affective disorders.Material and methods. 60 patients with CHF of II-III NYHA class 3-4 weeks after myocardial infarction with and anxious and depressive disorders were involved into the study. The patients were randomized in two groups. Patients of the first group received standard therapy (bisoprolol, lizinopril, simvastatin, acetylsalicylic acid, nitrates and diuretcs as required) in combination with pirlindol for 12 weeks. Patients of the second group received standard therapy alone. The follow-up period was 6 months. At baseline and after 12 and 24 weeks of therapy psychosomatic status was examined with the Beck questionnaire and HADS scale. Quality of life (QoL) survey with the Minnesota, Seattle and MOS SF- 36 questionnaires were performed as well as ECG with assessment of heart rate variability (HRV) and echocardiography.Results. Pirlindol improved QoL and was effective in correction of anxious and depressive disorders in CHF patients. At the end of the follow-up period normal Beck scores were registered in 90% and mild depression scores - in 10% of patients in pirlindol group. At the same time all patients of control group had depressive disorders of different intensity. Significant increase of left ventricular ejection fraction was observed in pirlindol group vs control group (20,9 vs -2,5%). Heart morphometric parameters improved in both groups, but left ventricle size reduction was more prominent in pirlindol group (-10,69 vs -5,34%). According to the spectral and time indexes of HRV, pirlindol treatment led to normalization of autonomic balance. Sympathetic overdrive was observed in patients of the control group.Conclusion. In elderly patients with CHF after myocardial infarction pirlindol taken additionally to the standard therapy is well tolerated, effectively eliminate psychosomatic disorders, results in significant improvement of morphofunctional cardiac condition and decrease of sympathetic over activity. Pirlindol can be recommended for the management of mild and moderate depressive disorders in elderly patients with CHF.
format Article
id doaj-art-eb0444f138344cd39f3ef60e92e767e2
institution Kabale University
issn 1819-6446
2225-3653
language English
publishDate 2016-01-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj-art-eb0444f138344cd39f3ef60e92e767e22025-08-23T10:00:26ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-0144475310.20996/1819-6446-2008-4-4-47-531136EFFICACY OF CHRONIC HEART FAILURE COMBINED THERAPY DURING PERLINDOL USAGE IN ELDERLY POST INFARCTION PATIENTS WITH PSYCHOSOMATIC DISORDERSM. E. Statsenko0I. A. Tyschenko1Chair of Internal Medicine of Volgograd State Medical University, Pavshikh Bortsov pl. 1, Volgograd, 400131 RussiaChair of Internal Medicine of Volgograd State Medical University, Pavshikh Bortsov pl. 1, Volgograd, 400131 RussiaAim. To study the efficacy and safety of reversible MAO inhibitor pirlindol (Pyrazidol) in elderly post infarction patients with chronic heart failure (CHF) and affective disorders.Material and methods. 60 patients with CHF of II-III NYHA class 3-4 weeks after myocardial infarction with and anxious and depressive disorders were involved into the study. The patients were randomized in two groups. Patients of the first group received standard therapy (bisoprolol, lizinopril, simvastatin, acetylsalicylic acid, nitrates and diuretcs as required) in combination with pirlindol for 12 weeks. Patients of the second group received standard therapy alone. The follow-up period was 6 months. At baseline and after 12 and 24 weeks of therapy psychosomatic status was examined with the Beck questionnaire and HADS scale. Quality of life (QoL) survey with the Minnesota, Seattle and MOS SF- 36 questionnaires were performed as well as ECG with assessment of heart rate variability (HRV) and echocardiography.Results. Pirlindol improved QoL and was effective in correction of anxious and depressive disorders in CHF patients. At the end of the follow-up period normal Beck scores were registered in 90% and mild depression scores - in 10% of patients in pirlindol group. At the same time all patients of control group had depressive disorders of different intensity. Significant increase of left ventricular ejection fraction was observed in pirlindol group vs control group (20,9 vs -2,5%). Heart morphometric parameters improved in both groups, but left ventricle size reduction was more prominent in pirlindol group (-10,69 vs -5,34%). According to the spectral and time indexes of HRV, pirlindol treatment led to normalization of autonomic balance. Sympathetic overdrive was observed in patients of the control group.Conclusion. In elderly patients with CHF after myocardial infarction pirlindol taken additionally to the standard therapy is well tolerated, effectively eliminate psychosomatic disorders, results in significant improvement of morphofunctional cardiac condition and decrease of sympathetic over activity. Pirlindol can be recommended for the management of mild and moderate depressive disorders in elderly patients with CHF.https://www.rpcardio.online/jour/article/view/1137pirlindolchronic heart failuredepressionquality of life
spellingShingle M. E. Statsenko
I. A. Tyschenko
EFFICACY OF CHRONIC HEART FAILURE COMBINED THERAPY DURING PERLINDOL USAGE IN ELDERLY POST INFARCTION PATIENTS WITH PSYCHOSOMATIC DISORDERS
Рациональная фармакотерапия в кардиологии
pirlindol
chronic heart failure
depression
quality of life
title EFFICACY OF CHRONIC HEART FAILURE COMBINED THERAPY DURING PERLINDOL USAGE IN ELDERLY POST INFARCTION PATIENTS WITH PSYCHOSOMATIC DISORDERS
title_full EFFICACY OF CHRONIC HEART FAILURE COMBINED THERAPY DURING PERLINDOL USAGE IN ELDERLY POST INFARCTION PATIENTS WITH PSYCHOSOMATIC DISORDERS
title_fullStr EFFICACY OF CHRONIC HEART FAILURE COMBINED THERAPY DURING PERLINDOL USAGE IN ELDERLY POST INFARCTION PATIENTS WITH PSYCHOSOMATIC DISORDERS
title_full_unstemmed EFFICACY OF CHRONIC HEART FAILURE COMBINED THERAPY DURING PERLINDOL USAGE IN ELDERLY POST INFARCTION PATIENTS WITH PSYCHOSOMATIC DISORDERS
title_short EFFICACY OF CHRONIC HEART FAILURE COMBINED THERAPY DURING PERLINDOL USAGE IN ELDERLY POST INFARCTION PATIENTS WITH PSYCHOSOMATIC DISORDERS
title_sort efficacy of chronic heart failure combined therapy during perlindol usage in elderly post infarction patients with psychosomatic disorders
topic pirlindol
chronic heart failure
depression
quality of life
url https://www.rpcardio.online/jour/article/view/1137
work_keys_str_mv AT mestatsenko efficacyofchronicheartfailurecombinedtherapyduringperlindolusageinelderlypostinfarctionpatientswithpsychosomaticdisorders
AT iatyschenko efficacyofchronicheartfailurecombinedtherapyduringperlindolusageinelderlypostinfarctionpatientswithpsychosomaticdisorders